Prelone (prednisolone oral solution) is a prescription compound used to help manage symptoms across numerous medical conditions. The therapeutic application of the medication involves addressing inflammation and modulating the immune system's response.

Quick Facts

• Helps manage symptoms of specific rheumatic conditions, such as rheumatoid arthritis and psoriatic arthritis.
• Used for a range of allergic conditions, including severe allergic rhinitis and asthma.
• May be part of a treatment plan for certain dermatologic diseases, such as pemphigus and severe psoriasis.
• Assists in the management of specific endocrine disorders and certain hematologic conditions.

The compound is indicated for use during acute episodes of gastrointestinal diseases, including ulcerative colitis and regional enteritis (Crohn’s disease). It may also be used in the palliative management of certain neoplastic diseases, such as leukemias and lymphomas.

Official Eligibility and Contraindications

Prelone (prednisolone) is broadly approved for use in both adult and pediatric populations for corticosteroid-responsive disorders. However, eligibility is strictly defined by regulatory warnings and contraindications.

Classification	Population or Condition
Absolute Contraindication	Patients with systemic fungal infections or known hypersensitivity to prednisolone. Also, patients receiving immunosuppressive doses must not receive live or live-attenuated vaccines [Source 1.3, 1.5].
Conditional Use/Caution	Hepatic impairment (cirrhosis) or renal insufficiency, as these conditions can enhance the drug's effect [Source 1.5, 1.6]. Patients with gastrointestinal disorders (e.g., active peptic ulcer, diverticulitis) require caution due to risks like perforation [Source 1.6].

Age and Reproductive Status:

For pediatric use, long-term therapy requires careful monitoring of growth and development [Source 1.7]. For specific forms/indications, safety in children under two years old is not established [Source 1.4]. The use of Prelone during pregnancy or lactation is permitted only after a risk-benefit assessment determines the potential benefits outweigh the potential hazards to the fetus or infant [Source 1.6].

Interactions with other medicines and products

Official Regulatory Interaction Profile

The interaction profile for Prelone (prednisolone) is strictly defined by government regulatory documents, detailing how co-administered substances or medical conditions affect the drug's activity, clearance, or contribute to additive risks.

Classification	Interacting Substance/Condition
Formal Restriction	Live Vaccines or Immunization Procedures (should not be administered due to risk of neurological complications and lack of antibody response).
Increased Exposure	Estrogens, Ketoconazole (documented to reduce clearance via CYP 3A4 inhibition, increasing plasma concentrations).
Decreased Exposure	Rifampin, Phenytoin (documented to increase metabolic clearance via CYP 3A4 induction, decreasing plasma concentrations).
Additive Risk	NSAIDs and Aspirin (increased risk of gastrointestinal ulceration/hemorrhage). Potassium-Depleting Diuretics (increased risk of hypokalemia).
Effect Enhancement	Hypothyroidism, Hepatic Impairment (Cirrhosis) (documented to enhance corticosteroid effect due to altered clearance).

These interactions create formal constraints on co-administration. Use with certain agents, such as Antidiabetic Agents, may require adjustment of the co-administered therapy due to Prelone's effect on blood glucose. The regulatory data notes that a high dietary intake of sodium may also exacerbate fluid retention associated with corticosteroid use.

Prelone, containing prednisolone, functions as a synthetic glucocorticoid receptor agonist. After passive diffusion across the cell membrane, prednisolone binds to the intracellular glucocorticoid receptor (GR), a member of the nuclear receptor superfamily (NR3C1). This binding event induces a conformational change, leading to the dissociation of chaperone proteins and the translocation of the activated steroid-receptor complex into the cell nucleus.

In the nucleus, the complex modulates gene transcription via two primary mechanisms. In the first mechanism, the complex binds directly to glucocorticoid response elements (GREs) on the DNA, leading to the transactivation of anti-inflammatory genes, such as those encoding Lipocortin-1 (Annexin A1). The increase in Lipocortin-1 subsequently inhibits phospholipase A2, which restricts the biosynthesis of eicosanoids, including prostaglandins and leukotrienes.

In the second mechanism, the complex engages in transrepression by interacting with and inhibiting pro-inflammatory transcription factors, such as NF-kappaB and AP-1. This interaction suppresses the transcription of numerous pro-inflammatory genes, including those encoding cytokines like TNF-alpha, interleukins, and chemokines. The net intracellular consequence is a systemic modulation of the immune response by altering gene expression across various cell types, primarily by reducing leukocyte migration and activity.

Prelone (Prednisolone Oral Solution) Administration Guidelines

Route of Administration: Oral (by mouth).

Dosing and Individualization

Administration of Prelone (prednisolone) dosage is highly variable and must be individualized based on the specific condition and the patient’s response to treatment. The initial daily dosage for adults generally ranges from 5 mg to 60 mg. For pediatric patients, the initial dose is typically determined by body weight, ranging from 0.14 to 2 mg/kg/day in divided doses.

After a favorable response is noted, the maintenance dosage should be reached by gradually decreasing the initial dose in small decrements to the lowest effective dosage that maintains an adequate clinical response.

---

Procedural Steps and Timing

Classification	Rule
Preparation	The oral liquid must be measured using a calibrated measuring device provided by the pharmacist to ensure accuracy. Household spoons should not be used.
Timing (General)	Take the medication with food or milk to minimize gastrointestinal (GI) irritation. If a single daily dose is prescribed, it is typically recommended to take it in the morning.
Missed Dose	If a dose is missed, take it as soon as it is remembered. If it is almost time for the next scheduled dose, skip the missed dose and return to the regular schedule. Do not take a double dose to make up for a missed one.
Stress Adjustment	If a patient on corticosteroid therapy is subjected to unusual stress (e.g., surgery, serious illness), an increased dosage of rapidly acting corticosteroids is indicated before, during, and after the stressful situation.

---

Discontinuation

Patients on long-term or high-dose therapy must not stop taking the medication abruptly. The dosage should be withdrawn gradually under a physician’s direction to allow the body's natural steroid production to recover and prevent signs of adrenal insufficiency.

Research Evidence / Overview of Studies for Prelone (Prednisolone)

Evidence for Use in Rheumatoid Arthritis and Chronic Inflammation

Research examining prednisolone in conditions like rheumatoid arthritis (RA) involves both short-term randomized controlled trials (RCTs) and long-term observational cohort studies. These studies were conducted during periods of increased symptom activity and focused on outcomes related to physical discomfort and systemic or functional imbalance. Researchers monitored changes in joint tenderness, swelling, and patient-reported outcomes describing perceived discomfort. Trials also examined how patient activity levels evolved during the study period.

For chronic RA, studies explored whether low-dose use monitored outcomes related to the structural progression of joints, with these outcomes monitored through radiographic evidence over defined time intervals. Findings describe patterns observed in the studies related to changes during short-term flares. Research describes changes measured during the study period, and these findings describe group patterns, not personal outcomes.

Evidence for Acute Asthma Exacerbations in Children

Prednisolone (Prelone) was evaluated in trials for acute or disruptive episodes, particularly in children experiencing asthma exacerbations. The study designs included randomized controlled trials and systematic reviews, where researchers explored changes in symptoms over courses lasting typically less than two weeks. Research monitored outcomes linked to inflammatory states, including the rates of subsequent hospitalizations or return visits to the clinic for worsening symptoms.

Trials reported measurements of the frequency of hospital admissions or relapses in the short-term follow-up period (3 to 14 days). Studies monitored the acceptability of the treatment.

What Remains Uncertain in the Research Landscape

Evidence highlights what is known, but also what is still uncertain. Data show patterns related to symptom changes in short-term studies, but certain gaps remain. Results apply only to the populations studied, and findings were mixed or inconsistent in some smaller, older comparative trials. Comparative evidence against all available alternatives is limited for some specific indications. Research does not determine whether an individual will respond similarly to the group patterns observed in these studies, and the study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. NICE Guideline: Rheumatoid arthritis in adults: management (NG185)

Common questions about Prelone (FAQ)

---

Q: Does Prelone treat the cause of inflammation or just the symptoms?

Official medical descriptions indicate that Prelone acts by modulating gene transcription and inhibiting the factors that lead to inflammation within your cells. By altering these core biological processes, the drug is described as modulating the inflammatory cascade at a molecular level.

---

Q: Can Prelone affect your mood or sleep?

Official labeling indicates that adverse reactions can include effects on the psychiatric and nervous system. These documented effects include insomnia (difficulty sleeping) and potential mood or behavioral changes.

---

Q: Is it common to feel jittery when starting Prelone?

While the specific term 'jittery' is not used in official regulatory labeling, reported adverse reactions related to the nervous system often include feelings of restlessness and nervousness.

---

Q: Are there any foods or drinks I should avoid while taking Prelone?

Official product information notes that a high dietary intake of sodium (salt) may exacerbate fluid retention, which is an associated effect of corticosteroid use. The official guidance emphasizes careful monitoring of sodium intake.

---

Q: Are there studies comparing Prelone to a placebo for inflammatory conditions?

Studies and official information indicate that the evidence supporting the use of prednisolone in approved conditions is based on rigorous research. This research includes findings from Randomized Controlled Trials (RCTs), which often involve comparing the drug's effects against an inactive substance (a placebo).

---

Q: What does 'use conditions' for Prelone mean?

In regulatory documents, the term 'use conditions' refers to the set of constraints and requirements governing the drug's use. This includes the officially approved medical disorders (indications), the necessary patient monitoring requirements, and all relevant contraindications (conditions where the drug should not be used).

---

Q: Is Prelone the same as prednisone?

Prelone's active ingredient is prednisolone, which is closely related to prednisone. Prednisone is chemically described as an inactive prodrug that is typically converted to the active prednisolone by the liver after ingestion. They are used for similar purposes.

---

Q: How quickly does Prelone start working?

According to the drug's pharmacokinetics data in official labeling, the maximum concentration of the active ingredient (prednisolone) in the bloodstream is typically reached within one to two hours after oral administration. This relates to the initial speed of the drug's absorption.

---

Q: Can Prelone be used for skin conditions?

Regulatory documents list prednisolone as officially approved for the treatment of various severe dermatologic diseases (skin disorders) that are known to be responsive to systemic corticosteroids.

---

Q: Does the form of Prelone (e.g., liquid, tablet) change how it works?

Official documents describe that all approved oral formulations, including the solution, syrup, or tablet, are designed to provide equivalent systemic exposure and function via the same underlying mechanism of action. The choice of form is primarily related to administration ease.

---

Q: How long does Prelone stay in your system after stopping?

Pharmacokinetic data in official labeling reports that the biological half-life of prednisolone in the bloodstream is typically between 18 and 36 hours. This indicates the rate at which the drug is processed and eliminated by the body.

---

Q: Is it possible for Prelone to stop working over time?

Regulatory guidance emphasizes the need for careful dosage adjustment, aiming for the lowest effective level that maintains an adequate response. This guidance indicates that the need for dosage adjustment should be evaluated over the course of therapy.

---

Q: Can I drive while taking Prelone?

Official labeling states that functional impairment may be observed. A review of side effects, such as visual disturbances or dizziness, should be considered before engaging in activities that demand mental alertness, such as driving.

---

Q: Is Prelone used for conditions related to the eyes?

Official regulatory documents indicate that prednisolone is used for the treatment of severe inflammatory and allergic processes involving the eye, provided these conditions are responsive to systemic corticosteroids.

---

Q: Does taking Prelone require any regular blood tests?

Regulatory documents specify patient monitoring requirements during therapy. This monitoring may require blood tests to assess factors such as blood glucose, electrolytes, and the function of the HPA axis (a hormone system).

---

Q: Is there a link between Prelone use and feeling dizzy?

Official lists of adverse reactions, which are compiled from regulatory sources, sometimes include reports of side effects such as dizziness or vertigo.

Storage and Disposal of Prelone (Prednisolone Oral Solution)

Prelone oral solution must be stored strictly according to regulatory labeling to maintain its stability.

---

Mandatory Storage Conditions

Requirement	Official Instruction
Temperature	Store at Controlled Room Temperature (15 C to 30 C / 59 F to 86 F).
Prohibitions	Do not refrigerate; protect from freezing.
Protection	Keep in the required tight and light-resistant container.
Child Safety	Must be dispensed in a child-resistant container and kept out of the reach of children.

---

Disposal Instructions

Unused or expired Prelone should be disposed of by following official guidelines. The preferred method is to utilize community drug take-back programs or authorized collectors. If a take-back program is unavailable, the medication should be mixed with an unappealing substance, placed in a sealed container, and discarded in the household trash.